Indian myocardial infraction market is estimated to grow modestly at a CAGR of around 8.9% during the forecast period. The availability of advanced treatment options in India with the increasing per capita healthcare expenditure is supporting the growth of the myocardial infarction market in the country. The government is actively focused on improving healthcare infrastructure in the country due to the growing number of chronic diseases including CVDs.

Request a Free Sample of our Report on Indian Myocardial Infraction Market: https://www.omrglobal.com/request-sample/india-myocardial-infarction-market

As per the Advance Medical Technology Association, the Indian healthcare industry was around $100 billion in 2016 which is expected to reach $175 billion in 2020. Around 77% of the total industry is accounts from hospitals, followed by pharmaceuticals with 14%, medical devices with 6%, and diagnostics with 3%. The pacemaker is one of the major medical devices contributing to the Indian medical device industry, as around 9.3% of the total revenue of the medical device industry is generating from the pacemaker and hearing aid combined. Most of the patient aids are imported from the US, China, Singapore, Australia, South Korea, and Ireland.

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters).

Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

A Full Report of Indian Myocardial Infraction Market is Available at https://www.omrglobal.com/industry-reports/india-myocardial-infarction-market

India Myocardial Infarction Market

By Type
• Non-ST-elevation myocardial infarction (NSTEMI)
• ST-elevation myocardial infarction (STEMI)
• Silent Heart Attacks

By Device
• Left Ventricular Assist Device (LVAD)
• Pacemaker
• Catheters
• Implantable Cardioverter-Defibrillator (ICD)
• Others (Stent Graft)

By Diagnosis
• Electrocardiography (ECG)
• Chest X-Ray
• Computed Tomography (CT Scan)
• Echocardiography
• Others (Blood Test)

By Treatment
• Medication
o Analgesics
o Thrombolytic
o Antiplatelet Agents
o Glycoprotein IIb/IIIa Inhibitors
o Others (Beta-Adrenergic Blockers)
• Surgery
o Angioplasty
o Bypass Surgery
o Heart Transplant

By End-User
• Hospital & Clinics
• Ambulatory Surgical Centers
• Research Institutes

Company Profiles
• Abbott Laboratories Inc.
• AstraZeneca PLC
• Bayer AG
• Boston Scientific Corp.
• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• Johnson & Johnson Services, Inc.
• Medtronic PLC
• Merck KGaA
• Mylan N.V.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/india-myocardial-infarction-market

About us:
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404